EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)

被引：0
|
作者：
Petrylak, D. P. [1 ]
Rosenberg, J. [2 ]
Duran, I. [3 ]
Loriot, Y. [4 ]
Sonpavde, G. [5 ]
Wu, C. [6 ]
Gartner, E. [7 ]
Melhem-Bertrandt, A. [8 ]
Powles, T. [9 ]
机构：
[1] Yale Univ, Sch Med, Med Oncol & Urol, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[3] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain
[4] Inst Gustave Roussy, Med Oncol, Paris, France
[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[6] Astellas Pharma US Inc, Biostat, Northbrook, IL USA
[7] Seattle Genet Inc, Expt Med, Bothell, WA USA
[8] Astellas Pharma US Inc, Dev Med Sci Oncol, Northbrook, IL USA
[9] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
922TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
    Li, Siming
    Shi, Yanxia
    Dong, Haiying
    Guo, Hongqian
    Xie, Yu
    Sun, Zhongquan
    Zhang, Xiaoping
    Kim, Eric
    Zhang, Jun
    Li, Yue
    Xu, Chenming
    Kadeerbai, Haishan
    Lee, Sue
    Gorla, Seema
    Guo, Jun
    Sheng, Xinan
    CANCER MEDICINE, 2024, 13 (21):
  • [22] Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Kaufman, Peter A.
    Awada, Ahmad
    Twelves, Chris
    Yelle, Louise
    Perez, Edith A.
    Velikova, Galina
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina E.
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 594 - U202
  • [23] Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC)
    Tsingas, Konstantinos
    Parikh, Ravi Bharat
    Elsouda, Dina
    Mucha, Lisa
    Fuldeore, Rupali
    Hubbard, Rebecca A.
    Mamtani, Ronac
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] EV-301 Long-Term Outcomes: 24-Month Findings From Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy in Previously Treated Advanced Urothelial Carcinoma
    Rosenberg, J.
    Powles, T.
    Sonpavde, G.
    Loriot, Y.
    Duran, I.
    Lee, J.
    Matsubara, N.
    Vulsteke, C.
    Castellano, D.
    Mamtani, R.
    Wu, C.
    Matsangou, M.
    Campbell, M.
    Petrylak, D.
    Cathomas, R.
    SWISS MEDICAL WEEKLY, 2022, 152 : 16S - 17S
  • [25] EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Rosenberg, J. E.
    Balar, A.
    O'Donnell, P. H.
    Heath, E. I.
    Hahn, N. M.
    Cavazos, N. M.
    Melhem-Bertrandt, A.
    Petrylak, D. P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [26] ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
    Grivas, Petros
    Vogelzang, Nicholas J.
    Alva, Ajjai Shivaram
    Feyerabend, Susan
    Loriot, Yohann
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Zakharia, Yousef
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [27] Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).
    Van der Heijden, Michiel Simon
    Gupta, Shilpa
    Galsky, Matt D.
    Derleth, Christina Louise
    Lee, Sue
    Kataria, Ritesh S.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [28] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Gupta, Shilpa
    Loriot, Yohan
    Van Der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Kikuchi, Eiji
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae-Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Moreno, Blanca Homet
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
    Rosenberg, Jonathan E.
    Heath, Elisabeth I.
    O'Donnell, Peter H.
    Hahn, Noah M.
    Balar, Arjun Vasant
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV plus P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).
    Gupta, Shilpa
    Loriot, Yohann
    van der Heijden, Michiel Simon
    Bedke, Jens
    Valderrama, Begona Perez
    Flechon, Aude
    Petrylak, Daniel P.
    De Santis, Maria
    Galsky, Matt D.
    Lee, Jae Lyun
    Swami, Umang
    Sridhar, Srikala S.
    De Giorgi, Ugo
    Wright, Phoebe
    Lu, Yi-Tsung
    Guan, Xuesong
    Dillon, Ryan
    Homet Moreno, Blanca
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 108 - 108
12345